- Form
- Compounded peptides, subcutaneous injection
- Price
- From $350/month (2 months $650, $325/month), confirmed after eligibility review
- Prescription
- Yes, clinician-prescribed for an individual patient
- FDA status
- Neither peptide FDA-approved; both recommended by an FDA advisory committee in July 2026, rulemaking pending
Wolverine Stack (BPC-157 + TB-500) is a compounded medication. Compounded medications are not FDA-approved, and the FDA has not reviewed them for safety, effectiveness or quality. What compounded means
How Wolverine Stack (BPC-157 + TB-500) works
BPC-157 is a 15-amino-acid peptide based on a gastric protein fragment; in animal studies it appears to influence blood vessel growth and repair signaling. TB-500 is a short synthetic fragment related to thymosin beta-4, a natural protein that binds actin and helps cells move to an injured area. The idea behind the stack is that the two act on different parts of repair, but this has not been tested in people.
Who it’s for, and who it isn’t
May be a fit
- Adults 18+ with a defined recovery goal who accept that the evidence is mostly animal research
- People whose injury has been properly assessed and who are already doing rehab or physical therapy
- People who have the foundations covered: sleep, protein, training load and time
- People willing to check in regularly with a clinician
Usually not a fit
- Anyone with active cancer or a history of cancer: thymosin beta-4 has been linked in laboratory research to tumor growth and spread
- Anyone pregnant, breastfeeding or trying to conceive
- Competitive athletes in drug-tested sport: both peptides are prohibited by WADA
- Injuries that need imaging, surgery or urgent care
- Anyone under 18
What’s included
- Online assessment and visit with a licensed clinician
- Review of injury history, cancer history, medications and sport participation
- Prescription only if appropriate and if a licensed pharmacy can lawfully dispense it
- Medication shipped from a licensed U.S. compounding pharmacy
- Follow-up visits to review progress and decide whether to continue
- No membership fee (labs priced separately)
Possible side effects
- Injection-site redness, itching, bruising or swelling
- Possible immune reactions to the peptides
- Other side effects have not been tracked systematically in people; report anything new to your clinician
- Unknown long-term effects, including theoretical concerns about cell growth
This isn’t a complete list. Your clinician reviews risks, interactions and warnings with you before prescribing. In an emergency, call 911.
What the evidence says
Evidence for each peptide is mostly preclinical. A 2025 systematic review found 35 animal studies and one small uncontrolled human series for BPC-157. Full-length thymosin beta-4 has been tested in early clinical trials for wounds and eye conditions, but TB-500 is a fragment, not the same molecule, and has no published controlled human trials. No study has tested the two together.
What is in the Wolverine Stack
The stack combines two peptides. BPC-157 is a synthetic chain of 15 amino acids modeled on a fragment of a protein in stomach juice. TB-500 is a short lab-made fragment related to thymosin beta-4, a protein your own cells make that helps them move and organize their internal scaffolding.
The name comes from the comic-book character known for rapid healing. That is marketing, not medicine. Nothing about this combination has been shown to make people heal faster.
The evidence, one peptide at a time
For BPC-157, a 2025 systematic review in HSS Journal included 36 studies on muscle, tendon, ligament and bone. Thirty-five were in animals. The only human report was 12 people with knee pain, with no comparison group, and the authors said human safety remains unknown.
Thymosin beta-4 has been studied more in people than BPC-157, in early trials for skin wounds, eye surface problems and heart injury. But those studies used the full protein or eye drops made from it. TB-500 is a smaller fragment, and results from the full protein cannot simply be assumed to apply.
No trial has combined BPC-157 and TB-500. Any added benefit from stacking them is a hypothesis.
Stack or single peptide?
Combining two experimental compounds means two sets of unknowns. If you react badly, it is harder to tell which one caused it. If you improve, it is hard to tell whether either one helped, since many injuries improve with time and rehab.
For that reason, a clinician may suggest starting with one peptide, or none, depending on your goals and history. The aim is a decision you can evaluate, not the most products at once.
FDA status of BPC-157 and TB-500 in 2026
Neither peptide is FDA-approved. Both were previously in Category 2 of the FDA's interim lists for compounding bulk substances. In April 2026 their nominations were withdrawn and the FDA moved them to its nominated-but-withdrawn list. For TB-500, the FDA's entry notes that the agency lacks important information about its safety.
On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding each peptide to the 503A bulks list. The proposed uses were ulcerative colitis for BPC-157 and wound healing for TB-500. These votes are advisory. The FDA still has to complete notice-and-comment rulemaking, and as of October 2026 it has not done so.
HealifyMD only arranges a prescription when a licensed pharmacy confirms it can dispense the product under current federal and state rules.
Cancer history and other safety questions
Because thymosin beta-4 helps cells move and form new blood vessels, anti-doping authorities and researchers have raised concern that it could encourage tumor growth or spread. This has not been settled in people, but it is a reason we do not prescribe this stack to anyone with active cancer and review any past cancer carefully.
Both peptides are prohibited at all times under the World Anti-Doping Agency list, and a therapeutic use exemption is not expected to be granted. If you compete in a tested sport, this stack is not for you.
Prescribed peptides versus 'research use only' vials
Both peptides are sold widely online with labels such as 'for research use only, not for human consumption.' Those products sit outside pharmacy oversight, so what is in the vial, how much, and whether it is sterile are all unknown.
A prescription from a licensed clinician, filled by a licensed U.S. pharmacy, does not make these peptides proven. It does mean that someone has reviewed your history, that the product comes through a regulated pharmacy, and that a clinician follows up with you and can tell you to stop.
Compounded medication and pricing
The Wolverine Stack is a compounded preparation made by a licensed pharmacy for one patient. Compounded drugs are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality. Your clinician sets dosing and duration; we do not publish home dosing schedules.
The price is from $350/month, or $650 for two months ($325/month), with no membership fee. It is confirmed during your eligibility review, and labs are priced separately. Care is available only in states where our clinicians are licensed.
Go deeper on Wolverine Stack (BPC-157 + TB-500)
Prescription treatments are available only to eligible patients after a clinical evaluation by an independently licensed clinician.
Wolverine Stack (BPC-157 + TB-500): common questions
Is the Wolverine Stack better than BPC-157 alone?
There is no evidence either way. No study has compared them, so the choice rests on your goals, history and tolerance for uncertainty.
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a short synthetic fragment related to thymosin beta-4, not the full protein. Findings from the full protein may not apply to the fragment.
Is either peptide FDA-approved?
No. An FDA advisory committee recommended both for the compounding bulks list in July 2026, but that is not approval and the rulemaking is not complete.
Are these peptides banned in sport?
Yes. BPC-157 is prohibited as a non-approved substance and thymosin beta-4 and its fragments are prohibited as growth factor modulators under the WADA list.
Is stacking riskier than one peptide?
It adds unknowns. Two experimental compounds make side effects harder to trace, which is why your clinician may start with one.
Can I use the stack after cancer treatment?
Usually not without detailed discussion with your oncology team, because of laboratory concerns that thymosin beta-4 may support tumor growth.
What if I see no change?
Your clinician reviews progress at follow-up. Stopping is a sensible choice when the evidence base is this early.
Sources
We cite government agencies, professional societies and peer-reviewed research. See our editorial policy.
- Certain bulk drug substances for use in compounding that may present significant safety risksU.S. Food and Drug Administration
- July 23-24, 2026 meeting of the Pharmacy Compounding Advisory CommitteeU.S. Food and Drug Administration
- Bulk-list bound? PCAC backs majority of peptides in two-day public meetingMcDermott Will & Schulte
- Emerging use of BPC-157 in orthopaedic sports medicine: a systematic reviewHSS Journal (via PubMed Central)
- Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applicationsPubMed (National Library of Medicine)
- Thymosin beta-4Sport Integrity Australia